ORAGENICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $37.7K | $131.5K | $87.0K | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $2.4M | $4.1M | $15.5M | $10.1M | $10.6M | $22.1M | $12.1M |
| SG&A Expense | — | $7.0M | $6.4M | $5.5M | $4.5M | $5.3M | $4.5M | $3.8M |
| Operating Income | — | $-9.4M | $-10.6M | $-20.9M | $-14.4M | $-15.8M | $-26.6M | $-15.9M |
| Operating Margin | — | — | — | -55,519.9% | -10,964.6% | -18,130.3% | — | — |
| Interest Expense | — | — | — | $30.6K | $15.1K | $15.8K | $10.7K | $7.3K |
| Pretax Income | — | $-10.0M | $-10.6M | $-20.7M | $-14.3M | $-15.7M | $-26.4M | $-15.6M |
| Income Tax Expense | — | $-136.9K | — | — | — | — | — | — |
| Net Income | — | $-9.8M | $-10.6M | $-20.7M | $-14.3M | $-15.7M | $-26.4M | $-15.6M |
| Net Margin | — | — | — | -54,858.1% | -10,864.0% | -18,062.0% | — | — |
| EPS (Basic) | — | $-4.56 | $-4.79 | $-0.92 | $-0.71 | $-0.81 | $-0.05 | $-0.04 |
| EPS (Diluted) | — | $-4.56 | $-4.79 | $-0.92 | $-0.71 | $-0.01 | $-0.05 | $-0.04 |
| Shares Outstanding (Basic) | 4.3M | 2.2M | 2.2M | 22.5M | 20.1M | 19.4M | 565.3M | 461.2M |
| Shares Outstanding (Diluted) | 4.3M | 2.2M | 2.2M | 22.5M | 20.1M | 19.4M | 565.3M | 461.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |